-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

634.O1.6 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Latest Data for Combination and Emerging Targeted Therapies in Myelofibrosis

Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
clinical trials, Research, adult, Translational Research, Non-Biological therapies, MPN, Clinical Research, Combination therapy, hematopoiesis, Chronic Myeloid Malignancies, patient-reported outcomes, Diseases, Therapies, Biological Processes, Myeloid Malignancies, Pharmacology, Study Population, Human
Saturday, December 10, 2022: 2:00 PM-3:30 PM
217-219 (Ernest N. Morial Convention Center)
Douglas Tremblay, MD, ARRAY(0xf5fcf4c) and Francesco Passamonti, MD, Università Degli Studi Dell'Insubria
Tremblay: Astellas Pharma: Research Funding; GSK: Consultancy; AbbVie: Consultancy. Passamonti: Novartis, Bristol-Myers Squibb/ Celgene, Abbvie, Roche, AOP Orphan.: Speakers Bureau; Novartis, Bristol-Myers Squibb/ Celgene, Sierra Oncology, Abbvie, Roche, AOP Orphan, Karyiopharma, Kyowa Kirin and MEI.: Consultancy.
In this session studies of combinations with ruxolitinib of studies of new single agents for myelofibrosis. This session mostly reports results of clinical trials
2:00 PM

Jean-Jacques Kiladjian, MD, PhD1,2,3, Jean-Christophe Ianotto, MD, PhD4*, Juliette Soret, MD5*, Nabih Maslah, PharmD, PhD6,7*, Cendrine Chaffaut8*, Françoise Boyer perrard9*, Fiorenza Barraco, MD10*, Viviane Dubruille, MD11*, Claude Capron12*, Amandine Tisserand13*, Valérie Rolland-Neyret14*, Zineb Ghrieb, PharmD5*, Sylvie Chevret, MD, PhD15*, Isabelle Plo16*, Marie-Hélène Schlageter, PharmD, PhD17*, Veronique Meignin18*, Matthieu Resche-Rigon, MD, PhD19* and Bruno Cassinat, PhD, PharmD20

1French Intergroup of Myeloproliferative neoplasms, FIM collaborative group, Paris, France
2Centre d'Investigations Cliniques (INSERM CIC 1427), AP-HP, Hôpital Saint-Louis, Université Paris Cité, Paris, France
3Saint-Louis Research Institute, INSERM UMR 1131, Paris, France
4Centre Hospitalier Universitaire, Brest, France
5Centre d'Investigations Cliniques, APHP, Hopital Saint-Louis, Paris, France
6Université de Paris, Cellular biology Department, Saint-Louis hospital, APHP, Paris, France
7IRSL, INSERM UMR 1131, Paris, France
8Division of Biostatistics, Saint-Louis Hospital, APHP, Paris, France
9Service des maladies du sang, Centre Hospitalier Universitaire d’Angers, Angers, France
10Department of Hematology, Centre Hospitalier Lyon Sud, Pierre Bénite, France
11Hematology Department, Nantes University Hospital, Nantes, France
12AP-HP Hopital Ambroise Paré, Boulogne, FRA
13Gustave Roussy, INSERM, UMR1170, Villejuif, France
14CHU de Grenoble, Grenoble, France
15Division of Biostatistics, Saint-Louis Hospital, APHP, Paris, France, Paris, France
16INSERM UMR1170, Gustave Roussy, Villejuif, FRA
17Service de Biologie Cellulaire, Hôpital Saint-Louis AP-HP, PARIS, France
18APHP, Hopital Saint-Louis, Anatomo-pathologie, PARIS, France
19Medical informatics and biostatistics department, CHU Saint-Louis, Paris, France
20Service de Biologie Cellulaire, APHP, Hopital Saint-Louis, Inserm UMRS1131, IRSL, Paris, FRA

2:15 PM

Abdulraheem Yacoub, MD1, Uma Borate, MD2, Raajit K Rampal, MD, PhD3, Haris Ali, MD4, Eunice Wang, MD5*, Aaron T. Gerds, MD, MS6, Gabriela S. Hobbs, MD7, Marina Kremyanskaya, MD, PhD8, Elliott Winton, MD9, Casey O’Connell, MD10*, Swati Goel, MD11*, Stephen T Oh, MD, PhD12, Gary J. Schiller, MD13, Albert Assad, MD14*, Sue Erickson-Viitanen, PhD14*, Feng Zhou, PhD14* and Naval Daver, MD15

1University of Kansas Cancer Center, Westwood, KS
2Oregon Health & Science University, Portland, OR
3Memorial Sloan Kettering Cancer Center, New York, NY
4City of Hope Medical Center, Duarte, CA
5Roswell Park Cancer Institute, BUFFALO, NY
6Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
7Massachusetts General Hospital, Boston, MA
8Icahn School of Medicine at Mount Sinai, New York, NY
9Emory University, Atlanta, GA
10University of Southern California, Los Angeles, CA
11Montefiore Medical Center, Bronx, NY
12Washington University School of Medicine, St. Louis, MO
13David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA
14Incyte Corporation, Wilmington, DE
15University of Texas MD Anderson Cancer Center, Houston, TX

2:30 PM

Francesco Passamonti, MD1*, James M. Foran, MD2, Anand Tandra, MD3*, Valerio De Stefano, MD4,5*, Maria Laura Fox, MD6*, Ahmad H. Mattour, MD7, Mary Frances McMullin, MD, FRCPath, FRCP8, Andrew Charles Perkins, MBBS, PhD, FRACP, FRCPA9, Gabriela Rodríguez-Macias, MD10*, Hassan Sibai, MBBS, MD11*, Qin Qin, PhD12*, Yan Sun, PhD12*, Jalaja Potluri, MD12, Jason Harb, PhD12* and Jonathan How, MD13

1Division of Hematology, University Hospital Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, University of Insubria, Varese, VA, Italy
2Division of Hematology/Oncology and Blood and Marrow Transplanation and Cellular Therapy, Mayo Clinic, Jacksonville, FL
3Indiana Blood and Marrow Transplant, Indianapolis, IN
4Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico A Gemelli, IRCCS, Rome, Italy
5Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
6Department of Hematology. Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron. Barcelona, Spain, Barcelona, Spain
7Henry Ford Hospital, Detroit, MI
8Centre for Medical Education, Queens University, Belfast, United Kingdom
9Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
10Department of Hematology, Gregorio Marañón General University Hospital (HGUGM), Madrid, Spain
11Leukemia Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
12AbbVie Inc., North Chicago, IL
13McGill University, Montreal, QC, CAN

2:45 PM

John Mascarenhas, MD1, Marina Kremyanskaya, MD, PhD2, Andrea Patriarca, MD3*, Vikas Gupta, MD, FRCP, FRCPath4, Francesca Palandri, PhD, MD5*, Timothy Devos, MD, PhD6, Raajit K Rampal, MD, PhD7, Moshe Talpaz, MD8, Alessandro Vannucchi, MD9, Andrew Kuykendall, MD10, Jean-Jacques Kiladjian, MD11, Srdan Verstovsek, MD, PhD12, Ruben Mesa, MD, FACP13, Gozde Colak, PhD14*, Qing Li, PhD15*, Sandra Klein, PhD14* and Claire N. Harrison, DM16

1Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
2Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
3Hematology Unit, Department of Translational Medicine, University of Eastern Piedmont and AOU Maggiore della Carità, Novara, Italy
4Department of Medicine, University of Toronto, Toronto, ON, Canada
5IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy
6University Hospitals Leuven and Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium
7Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY
8University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
9Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy
10Department of Malignant Hematology, H. Lee Mofitt Cancer Center, Tampa, FL
11Hôpital Saint-Louis, Université de Paris, Paris, France
12MD Anderson Cancer Center, Houston, TX
13Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
14Constellation Pharmaceuticals, Inc., a MorphoSys Company, Boston, MA
15MorphoSys US, Inc., Boston, MA
16Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

3:00 PM

Florian H Heidel, MD1*, Andrew Charles Perkins, MBBS, PhD2, Andreas Reiter, MD3, Carl C. Crodel, MD4*, Caroline Hasselbalch Riley, MD, PhD5*, María Teresa Gómez-Casares, MD, PhD6*, Istvan Takacs, MD7*, Heiko Becker, MD8*, Thomas Lehmann, MD9*, Olga Vinogradova, MD, PhD10,11,12*, Kate Burbury, MBBS, FRACP, FRCPA, DPhil13*, Alessandro M. Vannucchi, MD14*, Vikas Gupta, MD, FRCP, FRCPath15, Claire N. Harrison, DM16, Marielle Wondergem, MD, PhD17, Jean-Jacques Kiladjian, MD18, Grace Cleary, MPharm19*, Angela Zhang, PhD20*, Bruyère Mahuzier, PharmD21*, Jagannath Kota, PhD22*, Anirudh Prahallad, PhD20* and David M Ross, MBBS, PhD, FRACP, FRCPA23*

1Klinik und Poliklinik für Innere Medizin C, Universitätsklinikum Greifswald, Greifswald, Germany
2Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
3Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany
4Innere Medizin 2, Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany
5Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
6Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
7Semmelweis University, Budapest, Hungary
8Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Freiburg, Germany
9Clinic for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
10Hematology Center of Botkin Hospital, Moscow, Russian Federation
11Dmitry Rogachev National Research Center of Pediatric Hematology/Oncology and Immunology, Moscow, Russian Federation
12Pirogov Russian National Research Medical University, Moscow, Russian Federation
13Peter MacCallum Cancer Centre, Melbourne, Australia
14Center for Research and Innovation of Myeloproliferative Neoplasms – CRIMM, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy
15Division of Medical Oncology and Hematology, University Health Network, Toronto, ON, Canada
16Guy's and St Thomas' NHS Foundation Trust, London, ENG, United Kingdom
17Department of Hematology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam, Netherlands
18Hopital Saint-Louis, Paris, France
19Novartis Ireland Limited, Dublin, Ireland
20Novartis Pharma AG, Basel, Switzerland
21Novartis Pharma S.A.S, Rueil-Malmaison, France
22Novartis Healthcare Pvt. Ltd, Hyderabad, India
23Royal Adelaide Hospital and SA Pathology, Adelaide, Australia

3:15 PM

Firas El Chaer, MD1, James McCloskey, MD2*, Lindsay A.M. Rein, MD3, Randy A. Brown, MD4, Steven D. Green, MD5*, Jeffrey J. Pu, MD, PhD6, Shuichi Shirane, MD, PhD7*, Kazuya Shimoda, MD, PhD8, Michiko Ichii, MD, PhD9*, Junichiro Yuda, MD, PhD10*, Joseph Scandura, MD, PhD11, Sujan Kabir, MD12*, Jason M Foulks, PhD13*, Jian Mei, PharmD12*, Huyuan Yang, PhD12*, Mark Wade, PhD14*, Carl Stapinski, PharmD12*, Claudia Lebedinsky, MD12 and Raajit K Rampal, MD, PhD15

1Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA
2John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
3Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC
4Division of Hematology & Oncology, Department of Medicine, Shands HealthCare & University of Florida, Gainesville, FL
5Department of Medicine, Leukemia Division, Roswell Park Comprehensive Cancer Center, Buffalo, NY
6University of Arizona Cancer Center, Tucson, AZ
7Division of Hematology, Juntendo University School of Medicine, Tokyo, Japan
8University of Miyazaki, Miyazaki, Japan
9Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita City, Japan
10Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan
11Richard T. Silver, M.D. Myeloproliferative Neoplasms (MPN) Center, Weill Cornell Medicine, New York, NY
12Sumitomo Pharma Oncology, Inc., Marlborough, MA
13Sumitomo Pharma Oncology, Lehi, UT
14Sumitomo Pharma Oncology, Inc., Lehi, UT
15Memorial Sloan Kettering Cancer Center, New York, NY

*signifies non-member of ASH